By Samuel Indyk
Investing.com – Abingdon Health (LON:ABDX) has today announced the launch of the BioSURE COVID-19 IgG antibody self test. This follows an update in July, where Abingdon said they had signed an exclusive manufacturing agreement with BioSURE.
The new test, of which BioSURE is the legal manufacturer, has been CE market specifically for self-testing and can produce results in 20 minutes.
The test will allow individuals to know and monitor their own antibody status pre-vaccination, post-vaccination, and following infection.
The test has successfully completed technical transfer to manufacture following a pilot production run and is now in full manufacture at Abingdon’s manufacturing facilities in Yorkshire, UK.
“We are delighted that BioSure have launched their product and equally happy to be their manufacturing partner,” said Abingdon Health CEO Chris Yates.
“This initiative allows us to build on our long-term collaboration with the BioSure team for whom we manufacture their HIV self-test in the same format as this new test.
“This is the first of several products we have previously noted to be going through the technical transfer process with others for COVID antigen and non-COVID applications to follow and which we expect to contribute to contract manufacturing revenue growth.”
At 14:27BST, shares in Abingdon Health were trading higher by 67.2% at 50.99 pence per share.
Antibody Tests
The update also comes at a time when the UK government has announced a new scheme offering antibody tests to the public.
Anyone over the age of 18 will be able to opt in when having a PCR test from Tuesday. Of those who test positive, up to 8,000 will be sent two home antibody tests.
“Our new national antibody testing will be quick and easy to take part in, and by doing so you’ll be helping strengthen our understanding of COVID-19 as we cautiously return to a more normal life,” said UK Health Secretary Sajid Javid.
The new initiative aims to improve the understanding of the protection provided b antibodies generated following COVID-19 infection and vaccination.